Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-08-05Clinical Trial Update: A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial comparing subcutaneous versus intravenous rituximab in follicular non-Hodgkin's lymphoma completed with posted results.
-
FDA approval · 2015-08-04FDA Approved: MOZOBIL — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approves a supplemental application for MOZOBIL (plerixafor) from Sanofi-Aventis U.S. LLC. The action updates the product's labeling and…
-
CLINICAL_TRIALS trial_result · 2015-08-03Clinical Trial Update: Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach [Phase 2]
Phase 2 trial evaluating an anti-angiogenic approach for relapsed lymphoid malignancies, including Non-Hodgkin lymphoma, has been terminated…
-
CLINICAL_TRIALS trial_result · 2015-07-28Clinical Trial Update: Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms [Phase 1]
Termination of a Phase 1 trial evaluating oral azacitidine (CC-486) in Japanese subjects with hematological neoplasms.
-
CLINICAL_TRIALS trial_result · 2015-07-23Clinical Trial Update: A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma [Phase 3]
This is a Phase 3 clinical trial update evaluating MabThera (rituximab) in patients with advanced non-Hodgkin lymphoma. Results from the stu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-07-20Clinical Trial Update: Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease [Phase 3]
A Phase 3 trial investigating treatment for graft-versus-host disease in patients with recurrent or refractory lymphoma or Hodgkin's disease…
-
EMA withdrawal · 2015-07-17EMA Refused: Lympreva (dasiprotimut-t) — Biovest Europe Ltd
EMA refused approval for Lympreva (dasiprotimut-t) by Biovest Europe Ltd for lymphoid malignancies.
-
CLINICAL_TRIALS research · 2015-07-15Clinical Trial Update: Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating cytokine-induced killer (CIK) cell therapy for patients with refractory non-Hodgkin lymphoma; the study …
-
CLINICAL_TRIALS trial_result · 2015-07-10Clinical Trial Update: Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy [Phase 2, Phase 3]
This update summarizes a Phase 2/Phase 3 study of StemEx for high-risk hematologic malignancies after myeloablative therapy, focusing on eff…
-
FDA approval · 2015-07-08FDA Approved: TREANDA — Supplemental Application (Cephalon, LLC)
FDA approved a supplemental application for TREANDA (bendamustine hydrochloride) submitted by Cephalon, LLC.
-
CLINICAL_TRIALS trial_result · 2015-07-08Clinical Trial Update: Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
This entry reports a completed clinical trial evaluating the psychosexual impact of cancer-related infertility in women and the role of thir…
-
CLINICAL_TRIALS trial_result · 2015-07-01Clinical Trial Update: MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 trial of MGCD0103 in combination with azacitidine (Vidaza) for relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma ha…
-
CLINICAL_TRIALS trial_result · 2015-06-22Clinical Trial Update: Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy [Phase 1]
Phase 1 clinical trial evaluating the safety, tolerability, and biological activity of oral clioquinol in patients with relapsed or refracto…
-
CLINICAL_TRIALS trial_result · 2015-06-08Clinical Trial Update: Phase I Study of OPB-51602 in Patients With Hematologic Malignancies [Phase 1]
Phase I trial results are reported for OPB-51602 in patients with hematologic malignancies including multiple myeloma, non-Hodgkin lymphoma,…
-
CLINICAL_TRIALS trial_result · 2015-06-08Clinical Trial Update: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. [Phase 4]
Phase 4 study evaluating maintenance rituximab (MabThera) in patients with Non-Hodgkin's Lymphoma has completed; results were posted in 2015…
-
FDA approval · 2015-06-01FDA Approved: MITOXANTRONE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for mitoxantrone hydrochloride, submitted by Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS withdrawal · 2015-05-06Clinical Trial Update: The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma
The trial evaluating whether interim PET/CT after two cycles of chemotherapy can predict progression in non-Hodgkin lymphoma has been withdr…
-
CLINICAL_TRIALS research · 2015-05-05Clinical Trial Update: ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial of ESHAP-Imatinib for refractory/relapsed Non-Hodgkin lymphoma is underway. The current status is unknown.
-
CLINICAL_TRIALS withdrawal · 2015-04-28Clinical Trial Update: BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 trial of BL22 immunotoxin in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2015-04-20Clinical Trial Update: Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) [Phase 1]
Phase 1 update on weekly dosing of SCH 727965 in patients with advanced cancer, including solid tumors, non-Hodgkin lymphoma, multiple myelo…
-
CLINICAL_TRIALS withdrawal · 2015-04-17Clinical Trial Update: A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen [Phase 3]
A Phase 3 trial comparing two radioimmunotherapy regimens (I-131 tositumomab vs ibritumomab tiuxetan) for follicular and other non-Hodgkin l…
-
CLINICAL_TRIALS trial_result · 2015-04-15Clinical Trial Update: Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease [Phase 2]
Phase 2 trial update reporting completion of a study evaluating interleukin-12 in patients with various previously treated non-Hodgkin lymph…
-
CLINICAL_TRIALS trial_result · 2015-04-03Clinical Trial Update: Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL) [Phase 1, Phase 2]
This report summarizes the completion and results posting of a Phase 1/2 trial evaluating Bendamustine plus Bortezomib in indolent non-Hodgk…
-
CLINICAL_TRIALS trial_result · 2015-03-26Clinical Trial Update: Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma [Phase 1]
This is a Phase 1 trial evaluating a chemotherapy regimen followed by autologous stem cell transplantation and white blood cell infusions in…
-
CLINICAL_TRIALS trial_result · 2015-03-26Clinical Trial Update: Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL [Phase 1, Phase 2]
A Phase 1/2 trial of rituximab plus CAMPATH in relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma was terminated.